Announcements Trials
Browse Landscape

Phase

Phase 1/2 6Phase 2 5Phase 1 5Phase 3 1Phase 2/3 1

Status

Completed 3Recruiting 2

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Sarcoma 5Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Colorectal Neoplasms 55Neoplasms 31Unspecified Adult Solid Tumor, Protocol Specific 30Pancreatic Neoplasms 27Neoplasm Metastasis 24Colonic Neoplasms 23Stomach Neoplasms 22Rectal Neoplasms 20Neuroblastoma 15Lung Neoplasms 13Esophageal Neoplasms 12Glioblastoma 11Central Nervous System Neoplasms 11Carcinoma, Non-Small-Cell Lung 11Brain Neoplasms 11Astrocytoma 11Small Cell Lung Carcinoma 9Glioma 9Oligodendroglioma 8Gliosarcoma 8Breast Neoplasms 8Esophageal Squamous Cell Carcinoma 7Adenocarcinoma 7Unspecified Childhood Solid Tumor, Protocol Specific 6Ovarian Neoplasms 6Gallbladder Neoplasms 6Carcinoma, Hepatocellular 6Bile Duct Neoplasms 6Triple Negative Breast Neoplasms 5Solid Tumor 5

Interventions

Cyclophosphamide 9Topotecan 5Temozolomide 5Melphalan 5Irinotecan 5Busulfan 5fludarabine 4Granulocyte Colony-Stimulating Factor 4Filgrastim 4liposomal doxorubicin 3fludarabine phosphate 3cabozantinib 3Vincristine 3regorafenib 2pegfilgrastim 2Sirolimus 2Doxorubicin 2Bone Marrow Transplantation 2trioctyl phosphine oxide 1trifluridine tipiracil drug combination 1thymoglobulin 1talazoparib 1selinexor 1seclidemstat 1racotumomab 1poly ICLC 1pembrolizumab 1pegylated granulocyte colony-stimulating factor 1olaparib 1niraparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1 × Sarcoma, Ewing × Irinotecan × Clear all
NCT03715933 2026-05-22

Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

Inhibrx Biosciences, Inc

Phase 1 Recruiting
411 enrolled
Sarcoma

Sarcoma, Sarcoma, Ewing

NCT07194044 2026-05-15

METTSEO

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Recruiting
15 enrolled
Sarcoma

Sarcoma, Ewing

NCT01858168 2025-12-19

Phase I Study of Olaparib and Temozolomide for Ewings Sarcoma or Rhabdoomyosarcoma

Massachusetts General Hospital

Phase 1 Completed
49 enrolled
Sarcoma

Rhabdomyosarcoma, Sarcoma, Ewing

NCT02085148 2024-04-22

A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy

Bayer

Phase 1 Completed
62 enrolled
CNSGastrointestinalGenitourinarySarcoma

Neoplasms, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Hepatoblastoma

NCT02044120 2021-01-12

ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide and/or Irinotecan Patients With Previously Treated, Incurable Ewing Sarcoma

Sarcoma Alliance for Research through Collaboration

Phase 1 Completed
34 enrolled
Sarcoma

Sarcoma, Ewing

Data powered by HemOnc (CC BY 4.0) Colophon âš¡